Effect of everolimus on cell viability in nonfunctioning pituitary adenomas.

@article{Zatelli2010EffectOE,
  title={Effect of everolimus on cell viability in nonfunctioning pituitary adenomas.},
  author={Maria Chiara Zatelli and Mariella Minoia and Carlo Filieri and Federico Tagliati and Mattia Buratto and Maria Rosaria Ambrosio and Marcello Lapparelli and Massimo Scanarini and Ettore Ciro degli Uberti},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2010},
  volume={95 2},
  pages={
          968-76
        }
}
CONTEXT Pituitary adenomas can cause specific syndromes due to hormone excess and/or determine sellar mass symptoms. Pituitary cell growth can sometimes be influenced by medical therapy, such as for somatotroph adenomas treated with somatostatin analogs or prolactinomas treated with dopaminergic drugs. However, nonfunctioning pituitary adenomas (NFAs) are still orphans of medical therapy. Everolimus (RAD001), a derivative of rapamycin, is a well-known immunosuppressant drug, which has been… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Evidence for differential effects of selective somatostatin receptor subtypeagonistson -subunitandchromograninasecretionandoncell viability in human nonfunctioning pituitary adenomas in vitro

  • MC Zatelli, D Piccin, +8 authors EC degli Uberti
  • J Clin Endocrinol Metab
  • 2004
Highly Influential
6 Excerpts

Efficacyofadopamine-somatostatinchimericmolecule,BIM-23A760, in the control of cell growth from primary cultures of human nonfunctioning pituitary adenomas: a multi-center study

  • T Florio, F Barbieri, +14 authors P Jaquet
  • Endocr Relat Cancer
  • 2008
3 Excerpts

Similar Papers

Loading similar papers…